BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

539997

KPL

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Kwality Pharmaceuticals Limite Share Price Update

As of the latest trading session, Kwality Pharmaceuticals Limite share price is currently at ₹ 716.85, which is down by ₹ -25.40 from its previous closing. Today, the stock has fluctuated between ₹ 700.00 and ₹ 759.35. Over the past year, Kwality Pharmaceuticals Limite has achieved a return of 43.52 %. In the last month alone, the return has been -16.07 %. Read More...

Kwality Pharmaceuticals Limite fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    743.81

  • P/E Ratio (TTM)

    24.89

  • Beta

    0.82

  • Book Value / share

    233.21

  • Return on equity

    13.74%

  • EPS (TTM)

    33.96

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    8.54

info icon alternate text

Kwality Pharmaceuticals Limite Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 84.41
Operating Expense 73.65
Net Profit 8.54
Net Profit Margin (%) 10.11
Earnings Per Share (EPS) 8.23
EBITDA 18.16
Effective Tax Rate (%) 25.15
Particulars SEP 2024 (Values in Cr)
Revenue 90.03
Operating Expense 77.67
Net Profit 8.49
Net Profit Margin (%) 9.43
Earnings Per Share (EPS) 8.18
EBITDA 19.90
Effective Tax Rate (%) 32.59
Particulars JUN 2024 (Values in Cr)
Revenue 80.08
Operating Expense 69.22
Net Profit 8.37
Net Profit Margin (%) 10.45
Earnings Per Share (EPS) 8.06
EBITDA 17.64
Effective Tax Rate (%) 24.86
Particulars MAR 2024 (Values in Cr)
Revenue 91.98
Operating Expense 79.22
Net Profit 4.50
Net Profit Margin (%) 4.89
Earnings Per Share (EPS) 4.33
EBITDA 14.34
Effective Tax Rate (%) 28.04
Particulars DEC 2023 (Values in Cr)
Revenue 78.10
Operating Expense 68.93
Net Profit 7.70
Net Profit Margin (%) 9.85
Earnings Per Share (EPS) 7.42
EBITDA 17.32
Effective Tax Rate (%) 21.16
Particulars MAR 2024 (Values in Cr)
Revenue 307.17
Operating Expense 270.44
Net Profit 23.98
Net Profit Margin (%) 7.80
Earnings Per Share (EPS) 23.11
EBITDA 61.37
Effective Tax Rate (%) 23.76
Particulars MAR 2023 (Values in Cr)
Revenue 250.99
Operating Expense 211.64
Net Profit 19.47
Net Profit Margin (%) 7.75
Earnings Per Share (EPS) 18.45
EBITDA 46.70
Effective Tax Rate (%) 24.41
Particulars MAR 2022 (Values in Cr)
Revenue 456.13
Operating Expense 297.97
Net Profit 120.05
Net Profit Margin (%) 26.31
Earnings Per Share (EPS) 115.70
EBITDA 175.22
Effective Tax Rate (%) 25.74
Particulars MAR 2021 (Values in Cr)
Revenue 261.50
Operating Expense 241.29
Net Profit 15.42
Net Profit Margin (%) 5.89
Earnings Per Share (EPS) 14.86
EBITDA 30.85
Effective Tax Rate (%) 29.26
Particulars MAR 2020 (Values in Cr)
Revenue 138.68
Operating Expense 131.47
Net Profit 8.43
Net Profit Margin (%) 6.07
Earnings Per Share (EPS) 8.13
EBITDA 18.03
Effective Tax Rate (%) 24.32
Particulars MAR 2024 (Values in Cr)
Book Value / Share 215.31
ROE % 13.66
ROCE % 15.86
Total Debt to Total Equity 0.45
EBITDA Margin 22.19
Particulars MAR 2023 (Values in Cr)
Book Value / Share 192.48
ROE % 16.57
ROCE % 18.50
Total Debt to Total Equity 0.38
EBITDA Margin 25.34
Particulars MAR 2022 (Values in Cr)
Book Value / Share 173.81
ROE % 99.66
ROCE % 94.93
Total Debt to Total Equity 0.40
EBITDA Margin 38.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 58.16
ROE % 28.21
ROCE % 23.78
Total Debt to Total Equity 0.72
EBITDA Margin 11.62
Particulars MAR 2020 (Values in Cr)
Book Value / Share 43.57
ROE % 20.10
ROCE % 17.26
Total Debt to Total Equity 0.78
EBITDA Margin 12.83
Particulars MAR 2024 (Values in Cr)
Book Value / Share 216.98
ROE % 13.74
ROCE % 15.90
Total Debt to Total Equity 0.44
EBITDA Margin 22.29
Particulars MAR 2023 (Values in Cr)
Book Value / Share 193.93
ROE % 16.56
ROCE % 18.47
Total Debt to Total Equity 0.38
EBITDA Margin 25.41
Particulars MAR 2022 (Values in Cr)
Book Value / Share 175.17
ROE % 98.62
ROCE % 94.24
Total Debt to Total Equity 0.39
EBITDA Margin 38.42
Particulars MAR 2021 (Values in Cr)
Book Value / Share 59.47
ROE % 28.55
ROCE % 23.96
Total Debt to Total Equity 0.71
EBITDA Margin 11.80
Particulars MAR 2020 (Values in Cr)
Book Value / Share 44.62
ROE % 20.03
ROCE % 17.33
Total Debt to Total Equity 0.75
EBITDA Margin 13.02
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.94
Total Assets 394.20
Total Liabilities 394.20
Total Equity 222.58
Share Outstanding 10376198
Price to Book Ratio 1.89
Return on Assets (%) 6.03
Return on Capital (%) 7.42
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 7.36
Total Assets 353.63
Total Liabilities 353.63
Total Equity 199.06
Share Outstanding 10376198
Price to Book Ratio 1.59
Return on Assets (%) 5.47
Return on Capital (%) 6.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 12.95
Total Assets 340.59
Total Liabilities 340.59
Total Equity 179.78
Share Outstanding 10376198
Price to Book Ratio 3.31
Return on Assets (%) 35.23
Return on Capital (%) 51.32
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.80
Total Assets 166.26
Total Liabilities 166.26
Total Equity 59.85
Share Outstanding 10376198
Price to Book Ratio 0.94
Return on Assets (%) 9.10
Return on Capital (%) 16.02
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.53
Total Assets 132.69
Total Liabilities 132.69
Total Equity 44.96
Share Outstanding 10376198
Price to Book Ratio 0.57
Return on Assets (%) 6.26
Return on Capital (%) 10.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.03
Total Assets 397.57
Total Liabilities 397.57
Total Equity 225.94
Share Outstanding 10376198
Price to Book Ratio 1.89
Return on Assets (%) 6.03
Return on Capital (%) 7.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 6.09
Total Assets 356.58
Total Liabilities 356.58
Total Equity 202.02
Share Outstanding 10376198
Price to Book Ratio 1.59
Return on Assets (%) 5.45
Return on Capital (%) 6.66
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 10.87
Total Assets 342.67
Total Liabilities 342.67
Total Equity 182.55
Share Outstanding 10376198
Price to Book Ratio 3.31
Return on Assets (%) 35.03
Return on Capital (%) 50.75
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.13
Total Assets 168.78
Total Liabilities 168.78
Total Equity 62.50
Share Outstanding 10376198
Price to Book Ratio 0.94
Return on Assets (%) 9.13
Return on Capital (%) 15.85
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.14
Total Assets 134.68
Total Liabilities 134.68
Total Equity 47.09
Share Outstanding 10376198
Price to Book Ratio 0.57
Return on Assets (%) 6.26
Return on Capital (%) 10.74
Particulars MAR 2024 (Values in Cr)
Net Income 31.09
Cash from Operations 44.28
Cash from Investing -26.39
Cash from Financing -17.39
Net change in Cash -0.81
Free Cash Flow 74.12
Particulars MAR 2023 (Values in Cr)
Net Income 25.57
Cash from Operations 47.53
Cash from Investing -48.44
Cash from Financing 0.99
Net change in Cash -6.06
Free Cash Flow 95.21
Particulars MAR 2022 (Values in Cr)
Net Income 161.56
Cash from Operations 101.95
Cash from Investing -62.92
Cash from Financing 5.65
Net change in Cash 3.32
Free Cash Flow 157.10
Particulars MAR 2021 (Values in Cr)
Net Income 21.27
Cash from Operations 33.08
Cash from Investing -23.20
Cash from Financing 0.76
Net change in Cash 4.27
Free Cash Flow 56.48
Particulars MAR 2020 (Values in Cr)
Net Income 10.91
Cash from Operations 8.87
Cash from Investing -17.79
Cash from Financing 11.77
Net change in Cash 0.13
Free Cash Flow 29.65
Particulars MAR 2024 (Values in Cr)
Net Income 31.46
Cash from Operations 44.64
Cash from Investing -26.39
Cash from Financing -17.39
Net change in Cash -0.44
Free Cash Flow 74.48
Particulars MAR 2023 (Values in Cr)
Net Income 25.76
Cash from Operations 48.34
Cash from Investing -48.44
Cash from Financing 0.99
Net change in Cash -5.25
Free Cash Flow 96.01
Particulars MAR 2022 (Values in Cr)
Net Income 161.67
Cash from Operations 100.59
Cash from Investing -62.97
Cash from Financing 5.65
Net change in Cash 1.92
Free Cash Flow 155.75
Particulars MAR 2021 (Values in Cr)
Net Income 21.79
Cash from Operations 32.73
Cash from Investing -23.19
Cash from Financing 0.82
Net change in Cash 3.98
Free Cash Flow 56.13
Particulars MAR 2020 (Values in Cr)
Net Income 11.14
Cash from Operations 8.34
Cash from Investing -17.12
Cash from Financing 12.35
Net change in Cash 0.86
Free Cash Flow 29.08
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

Kwality Pharmaceuticals Limite Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
716.85 -3.42 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 747.10
  • 26 Days 775.10
  • 10 Days 767.10
  • 50 Days 775.60
  • 12 Days 771.40
  • 100 Days 781.00
  • 20 Days 776.20
  • 200 Days 742.70
750.67 PIVOT

First Support

727.58

First Resistance

765.33

Second Support

712.92

Second Resistance

788.42

Third Support

689.83

Third Resistance

803.08

RSI

40.14

ADX

19.41

MACD

-3.79

Williams % R

-92.34

Commodity Channel Index (CCI)

-158.06

Date

2025-04-30

Week

9131.00

Same Day

5108.00

Month

7176.00

1 Year

0.82

3 Year

0.58

Over 1 Month

-16.07%

down

Over 1 Year

43.52%

down

Over 3 Months

-17.62%

down

Over 3 Years

13.92%

down

Over 6 Months

-13.61%

down

Over 5 Years

82.92%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

Kwality Pharmaceuticals Limite shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
44.85%
Promoter Holdings
54.82%
FII
0.0%
DII
0.31%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Ramesh Arora 2698684.0 (26.01%) Shareholding of Promoter and Promoter Group
Ajay Arora 1410638.0 (13.59%) Shareholding of Promoter and Promoter Group
Aditya Arora 1240091.0 (11.95%) Shareholding of Promoter and Promoter Group
Deepak Bansal 1103174.0 (10.63%) Public Shareholding
Manohar Devabhaktuni 516735.0 (4.98%) Public Shareholding
Kadayam Ramnathan Bharat 205000.0 (1.98%) Public Shareholding
Dheeraj Kumar Lohia 198058.0 (1.91%) Public Shareholding
Jani Bhasha Shaik 150000.0 (1.45%) Public Shareholding
Anju Arora 135634.0 (1.31%) Shareholding of Promoter and Promoter Group
Onkar Singh 112200.0 (1.08%) Public Shareholding
Geeta Arora 111500.0 (1.07%) Shareholding of Promoter and Promoter Group
Jugal Kishore Huf 92350.0 (0.89%) Shareholding of Promoter and Promoter Group
Aarti Bajaj 75.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Kwality Pharmaceuticals Limite corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
05 Jan 2017 0.6 Interim 06 Jan 2017 Equity shares
Ex-Date Ex-Bonus Ratio
12 Oct 2017 11 Oct 2017 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Kwality Pharmaceuticals Limite Share Price

Kwality Pharmaceuticals Limited was Incorporated on May 4th 1983 when its founder Mr. Ramesh Arora was inspired to begin his own venture leaving behind the already flourishing family business of spinning and aromatics. With little background of finished pharmaceuticals and high held spirits and will, he started this business. He received his first drug license in 1981 approved for liquid oral manufacturing. Presently, the Company has 48 different sections available at their production centres.

Kwality Pharmaceuticals Ltd. are manufacturer of finished pharmaceutical formulations in a Liquid Orals, Dry Syrups, Tablets, Capsules, Sterile Powder for Injections and small volume injectables. The Company has the most modern & sophisticated Plant, Equipment, technique, and workforce. Certified as ISO: 9001:2015 and ISO 14001:2015, it is working with new SCHEDULE M and WHO norms and certified with GMP.

The Company is keeping all records of inputs used in manufacturing. The inputs are tested as per standard laid down by company SOP. The in-process testing records are also maintained as per SOP. Similarly, finished goods are also tested as per SOP and are then allowed for sale.

Apart from these, the Company is making medicines in various dosage forms like Liquid Orals, Powder for Oral Suspension, Tablets, Capsules, Dry Syrup, Syrup, Sterile Powder for Injections, small volume injectables, Ointments, External Preparations, ORS and many more in various categories like Beta Lactam & non-Beta Lactam, Hormones, Cytotoxic (Oncology) and Effervescent as per new GMP norms. Besides, it manufacture the latest drugs for the management of viral infections/diseases in different dosage forms. Each category of product is processed in a separate section, which is equipped with the latest machinery. All sections are supported by a centralized quality control department which has different segments. Each segment is equipped with the latest scientific machinery, ingredients, and trained staff supported by SOP. These segments are instrumental testing, chemical testing, pyrogen testing, and Bacterial endotoxin testing and microbiology, etc.

The Company had put up a multi-storied factory building in Nag Kalan, Amritsar, which started its production in March 2006. The new factory was as per WHO GMP norms. It put up the Jassur Plant in Himachal Pradesh. This unit was in the TAX-free zone, which has helped the Company to sell its Products into the Indian retail market. Kwality Pharmaceuticals, as an exporting company has supplied Remdesivir Injection to the global market and similarly Propofol injection was short in supply in various high profile countries who normally accept US FDA companies' products. But in shortage of medicine, they procured these injections from the Company and after seeing the performance and efficacy, they registered the product. They started procuring the other items of the Company and it became world recognized and now the booking grew which has yielded more sales and profit for the Company.

Parent organization Indian Private
NSE symbol [-]
Founded 1983
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Kwality Pharmaceuticals Ltd?

Answer Field

The share price of Kwality Pharmaceuticals Ltd for NSE is ₹ 0.00 and for BSE is ₹ 716.85.

What is the Market Cap of Kwality Pharmaceuticals Ltd?

Answer Field

The market cap of Kwality Pharmaceuticals Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 7,43.80 Cr. as of now.

What is the 52 Week High and Low of Kwality Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Kwality Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 1069.95 and ₹ 481.00.

How to Buy Kwality Pharmaceuticals Ltd share?

Answer Field

You can trade in Kwality Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Kwality Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 43.52%.

What is the Current Share Price of Kwality Pharmaceuticals Ltd?

Answer Field

Kwality Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 716.85 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Kwality Pharmaceuticals Ltd Share?

Answer Field

The market cap of Kwality Pharmaceuticals Ltd for NSE ₹ 0.0 & for BSE ₹ 7,43.80 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Kwality Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Kwality Pharmaceuticals Ltd share is 24.89.

What is the PB ratio of Kwality Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Kwality Pharmaceuticals Ltd share is 233.21.

How to Buy Kwality Pharmaceuticals Ltd Share?

Answer Field

You can trade in Kwality Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Kwality Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Kwality Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Kwality Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|